These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

785 related items for PubMed ID: 19037838

  • 1. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD, Huang L.
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficient and targeted delivery of siRNA in vivo.
    Shim MS, Kwon YJ.
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. siRNA delivery systems for cancer treatment.
    Oh YK, Park TG.
    Adv Drug Deliv Rev; 2009 Aug 10; 61(10):850-62. PubMed ID: 19422869
    [Abstract] [Full Text] [Related]

  • 6. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S, Zhao B, Jiang H, Wang B, Ma B.
    J Control Release; 2007 Oct 18; 123(1):1-10. PubMed ID: 17716771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R, Al Shaal L, Mishra PR.
    Pharmazie; 2011 May 18; 66(5):313-8. PubMed ID: 21699063
    [Abstract] [Full Text] [Related]

  • 9. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK, Hajeri PB.
    Drug Discov Today; 2009 Sep 18; 14(17-18):859-65. PubMed ID: 19540929
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ, Puri N, Won YY.
    J Control Release; 2007 Aug 16; 121(1-2):64-73. PubMed ID: 17588702
    [Abstract] [Full Text] [Related]

  • 12. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y, Nishikawa M, Takakura Y.
    Adv Drug Deliv Rev; 2009 Jul 25; 61(9):760-6. PubMed ID: 19386274
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhalable siRNA: potential as a therapeutic agent in the lungs.
    Durcan N, Murphy C, Cryan SA.
    Mol Pharm; 2008 Jul 25; 5(4):559-66. PubMed ID: 18491918
    [Abstract] [Full Text] [Related]

  • 17. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN.
    Acc Chem Res; 2012 Jul 17; 45(7):1163-71. PubMed ID: 22568781
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Advances in the development of siRNA-based therapeutics for cancer.
    Shen Y.
    IDrugs; 2008 Aug 17; 11(8):572-8. PubMed ID: 18683092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.